Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 3/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.39 |
| ▸ | PHGDH | O43175 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29690426 | 1.00 | NOTUM (0.48) | NOTUMMEN1KMT2AGAAMAOA | |
| SCHEMBL8110651 | 0.82 | MAOA (0.58) | NOTUMMEN1KMT2AMAOAMAOB | |
| SCHEMBL7760595 | 0.76 | TSHR (0.46) | MEN1KMT2AGAARXFP1ALDH1A1 | |
| SCHEMBL5894593 | 0.73 | ALDH1A1 (0.36) | NOTUMMEN1KMT2AGAAALDH1A1 | |
| SCHEMBL8246564 | 0.73 | TRAP1 (0.44) | NOTUMHSP90B1TRAP1 | |
| SCHEMBL11129044 | 0.71 | DRD2 (0.52) | NOTUMMEN1KMT2AMAOAMAOB | |
| SCHEMBL28923808 | 0.69 | SIGMAR1 (0.46) | CYP2D6NAMPT | |
| SCHEMBL27724288 | 0.69 | NOTUM (0.67) | NOTUMMEN1KMT2AMAPTHSP90AA1 | |
| SCHEMBL2358009 | 0.69 | CARM1 (0.46) | NOTUMMEN1KMT2AGAAMAOA | |
| SCHEMBL16938579 | 0.69 | MAOA (0.50) | NOTUMMEN1KMT2AGAAMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024054845-A1 | MACROCYCIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SIONNA THERAPEUTICS (US) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024015497-A1 | TYROSINE KINASE 2 INHIBITORS AND USES THEREOF | BIOGEN MA INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| WO-2023244554-A1 | CYCLIC PEPTIDES FOR TRAPPING INTERLEUKIN-1 BETA | MERCK SHARP & DOHME LLC (US) | 2023-12-21 | — | — | WO | disclosed |
| EP-4284798-A1 | IMIDAZO[1,2-A]PYRAZINE AND IMIDAZO[1,2-A]PYRIDINE BASED TYROSYL-DNA PHOSPHODIESTERASE I (TDP1) INHIBITORS | The USA, as represented by The Secretary, Department of Health and Human Services (US) | 2023-12-06 | — | — | EP | disclosed |
| WO-2023185073-A1 | PARP7 INHIBITOR AND USE THEREOF | 诺沃斯达药业(上海)有限公司 | 2023-10-05 | — | — | WO | disclosed |
| WO-2023140369-A1 | PHOSPHORIC ACID DERIVATIVES | Prism BioLab Co., Ltd. (JP) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023118576-A1 | DHODH INHIBITORS CONTAINING A CARBOXYLIC ACID BIOISOSTERE | IMMUNIC AG (DE) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023091565-A1 | NSD2-TARGETED CHEMICAL DEGRADERS AND COMPOSITIONS AND METHODS OF USE THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2023086220-A2 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023064185-A1 | HOMOGENOUS ENZYME LINKED IMMUNOASSAY | IDEXX LABORATORIES, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| WO-2018115591-A1 | PYRAN DERVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | ORION CORPORATION (FI) | 2018-06-28 | — | — | WO | disclosed |
| CN-106432225-A | Certain triazolopyridine compounds and triazolopyrazine compounds, compositions thereof and methods of use thereof | 和记黄埔医药（上海）有限公司 | 2017-02-22 | — | — | CN | disclosed |
| EP-3083587-A1 | OXIMINO DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA | Cadila Healthcare Limited (IN) | 2016-10-26 | — | — | EP | disclosed |
| CN-106008523-A | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | 阵列生物制药公司 | 2016-10-12 | — | — | CN | disclosed |
| WO-2015107541-A1 | OXIMINO DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA | CADILA HEALTHCARE LIMITED (IN) | 2015-07-23 | — | — | WO | disclosed |
| EP-2252595-A1 | OXIM DERIVATIVES AS HSP90 INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2010-11-24 | — | — | EP | disclosed |
| US-20100016396-A1 | PYRAZOLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128138-A1 | PYRAZOLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-12-02 | — | — | EP | disclosed |
| WO-2009097578-A1 | OXIM DERIVATIVES AS HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-06 | — | — | WO | disclosed |
| WO-2007124543-A1 | PROFLUORESCENT NITROXIDE COMPOUNDS | QUEENSLAND UNIVERSITY OF TECHNOLOGY (AU) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016396-A1 | PYRAZOLE COMPOUND | SLC5A1, SLC5A2, GLP1R | NOTUM 1111/4885MEN1 2280/4885KMT2A 2269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.